Cleared Traditional

K831090 - HEMATOXYLIN GILL FORMULATION IX#56016 (FDA 510(k) Clearance)

Class I Pathology device.

K831090 · Accra Laboratories, Inc. · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1983
Decision
65d
Days
Class 1
Risk

K831090 is an FDA 510(k) clearance for the HEMATOXYLIN GILL FORMULATION IX#56016. Classified as Hematoxylin (product code HYJ), Class I - General Controls.

Submitted by Accra Laboratories, Inc. (Mchenry, US). The FDA issued a Cleared decision on June 8, 1983 after a review of 65 days - a notably fast clearance cycle.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 864.1850 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Accra Laboratories, Inc. devices

Submission Details

510(k) Number K831090 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 04, 1983
Decision Date June 08, 1983
Days to Decision 65 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
12d faster than avg
Panel avg: 77d · This submission: 65d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HYJ Hematoxylin
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 864.1850
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.